Galapagos N.V. | 82.0000 / +4.41% |
Date/Time | 04/22 / 20:36 |
Chg. / Chg.(%) | 3.4600 / +4.41% |
Bid | - |
Ask | - |
Open | 82.9000 |
Previous Close | 78.5400 |
High | 82.9000 |
Low | 82.0000 |
Volume [USD] | 17,977.8000 |
Volume [Units] | 219 |
Price fixings | 3 |
ISIN | BE0003818359 |
Security | GLPGF |
Exchange | Nasdaq Other OTC |
Type | Stock |
Other Exchanges
Exchange | Last | Volume | |
---|---|---|---|
Euronext - A.. | 67.96 | ![]() |
149,813 |
Cboe Europe .. | 67.94 | ![]() |
46,433 |
Turquoise | 67.94 | ![]() |
16,541 |
London Inter.. | 68.00 | ![]() |
3,408 |
TradeGate | 68.71 | ![]() |
609 |
Xetra | 69.98 | ![]() |
300 |
Cboe Europe .. | 68.65 | ![]() |
145 |
Düsseldorf | 67.91 | ![]() |
0 |
München | 68.90 | ![]() |
0 |
Berlin | 67.83 | ![]() |
0 |
Frankfurt | 68.5900 | ![]() |
0 |
Lang & Schwa.. | 67.82 | ![]() |
|
gettex | 68.730 | ![]() |
|
Stuttgart | 68.730 | ![]() |
|
Cboe Europe .. | 69.07 | 416 | |
Nasdaq Other.. | 82.0000 | ![]() |
219 |
Vienna Globa.. | 68.96 | 0 |
News
- Gilead Sciences submits new drug application in Japan for filgotinib for the treatment of ulcerative colitis with an inadequate response to conventional therapies
06:01 - GlobeNewswire - OXURION NV to Present at Wet AMD and DME Drug Development Summit
04/13/2021 / 07:30 - GlobeNewswire - Extension of lock-up period in Gilead-Galapagos collaboration agreement
04/08/2021 / 22:01 - GlobeNewswire - Oxurion NV – Publication in Progress in Retinal Eye Research highlights the potential of pan-RGD integrin antagonists to improve the treatment of diabetic retinopathy and wet AMD
04/07/2021 / 17:45 - GlobeNewswire - Oxurion NV enters into a Capital Commitment of up to €30 Million with Negma Group
04/06/2021 / 07:30 - GlobeNewswire